Kierunki poszukiwania preparatów przeciwnowotworowych

• Autorzy: Mikiciuk-Olasik E. , Błaszczak-Świątkiewicz K.

Warianty tytułu

EN

New directions in the quest of anti-cancer agents

• Języki publikacji: PL

Abstrakty

EN

Cancer chemotherapy over twenty years has been under extremely intensive investigation. Failure in the treatment of neoplasms is due to characteristic fe-atures of cancer cells. Their structure delays and decreases the efficacy of drugs administered orally or intravenously. Therefore, greater emphasis is placed on the development of new molecular studies. The development of particular molecular diagnostic methods is based on new advances in immunology, genetics and nuclear medicine. Nuclear medicine concentrates on the diagnostics and treatment of various diseases, including neoplasms treated by means of radiopharmaceuticals. The isotope most commonly used as a source of g radiation for radiopharma-ceuticals is technetium (99mTc). The complexes of this radiotracer (e.g. 99mTc-HM-PAO, 99mTc-CB-PAO, 99mTc-ECD) are widely used for brain imaging. These compounds indicate areas of normal blood supply in the brain, but do not enter hypoxic tumour cells. The differences in oxygenation level between normal and cancer cells is key strategy used not only in the diagnostics, but also in the treatment of neoplasms. Some compounds [quinone antibiotics,nitroimidazoles, tirapazamine] are known as hypoxia selective agents activated in low oxygen concentrations. Another strategy used in anticancer therapy aims at the inhibition of angiogenesis in the tumour; other methods limit the growth of tumour - these include use of inhibitory enzymes such as telomerase inhibitors (phosphorothioate oligonucleotides, cisplatin) and polyamine metabolism inhibitors (DFMO, MGBG). Valuable antineoplastic drugs originate from natural sources. Currently, the derivatives of acronycine and spongiostatin are being investigated. Natural compounds with a documented anticancer activity include, for example, taxol , etopozide and tenipozide. New directions in the research of new compounds for use in the diagnostics and treatment of neoplastic diseases are closely related to the development of molecular studies, which offer explanation of complex patophysiology of tumours on molecular level. Also. medical chemistry plays an important role in modern investigation methods, such as molecular modelling.

Słowa kluczowe

PL

nowotwory; diagnostyka medyczna; terapia antynowotworowa; inhibitor

• Wydawca: Polskie Towarzystwo Chemiczne
• Czasopismo: Wiadomości Chemiczne
• Rocznik: 2000
• Tom: [Z] 54, 9-10
• Strony: 705--724
• Opis fizyczny: schem., bibliogr. 31 poz.

Twórcy

autor

Mikiciuk-Olasik E.

• Zakład Chemii Farmaceutycznej i Analizy Leków, Akademia Medyczna w Łodzi ul. Muszyńskiego 1, 90-151 Łódź

autor

Błaszczak-Świątkiewicz K.

• Zakład Chemii Farmaceutycznej i Analizy Leków, Akademia Medyczna w Łodzi ul. Muszyńskiego 1, 90-151 Łódź

• Zakład Chemii Farmaceutycznej i Analizy Leków, Akademia Medyczna w Łodzi ul. Muszyńskiego 1, 90-151 Łódź

Bibliografia

• [1] K. Jain, Bariery utrudniające wnikanie leków do guzów litych, Świat Nauki, 1994, 36.
• [2] Cz. Radzikowski, A. Opolski, J. Wietizyk, Post. Hig. Med. Dośw., 1998, 52. 553.
• [3] M. Wojtukiowicz, E. Matuszewska, L. Zimnoch, ibid., 1998, 52, 577.
• [4] G. Nawrocki, M. Nowacki, Nowotwory, 1999, 49, 94.
• [5] Textbook of Radiopharmacy Theory and Practice, Ed. Ch. B. Sampson, Addenbrooke’s Hos-pital Cambridge, UK, Gordon and Breach Publishers, 1995.
• [6] R. D. Neirinckx, L. R Canning. D. P. Nowotnik, J. Nucl. Men., 1987, 28, 191.
• [7] R. D. Neirinckx, J. F. Burjce, k. C. Harrison, J. Cereb. Blood Flow Metab., 1988, 8, 4.
• [8] J. M. Brown, Br. J. Cancer, 1993, 67, 1163.
• [9] A. Monge, J. A. Palop, J. Med. Chem., 1995, 38, 1786.
• [10] A. Nunn, K. Linder, H. W. Strauss, Eur. J. Nucl. Med., 1995, 22, 265
• [11] A. Monge, A. Lopez de Cerain, Pharmazie, 1998, 53, 758.
• [12] B. G. Siim, G. J. Atwell, J. Med. Chem., 1997, 40, 1381.
• [13] B. D. Palmer, W. R. Wilson, J. Med, Chem., 1994, 37, 2175.
• [14] W. A. Denny, W. R Wilson, Reviews, 1993, 12, 135.
• [15] J. K. Siwicki, Nowotwory, 1997, 47, 483.
• [16] E. K. Parkinson, Br. J. Cancer, 1996, 73, 1.
• [17] S. E. Hamilton, C. G. Simmons, Chem. Biol., 1999, 6, 343.
• [18] J. C. Norton, M. A. PiatyszeK, Nat. biotechnol., 1996, 14, 615.
• [19] J. E. Mata, S. S. Joshi, Toxicol. Appl. Pharmacol, 1997, 144, 189.
• [20] E. Izbicka, R. T. Wheelhouse, Cancer Res., 1999, 59, 6o9
• [21] T. M. Fletcher, M. Salazar, Biochemistry, 1996, 35, 15611.
• [22] A. M. Burger, J. A. Double, Eur. J. Cancer, 1997, 33, 638.
• [23] P. P. McCann, A. E. Pegg, A. Sjoerdsma, Inhibition ofPolyamim Metabolism, Academie Press Inc., Ed. Peter P. Mc Cann, Orlando Floride, 1987.
• [24] P. B. Schift, J. Font, S. B. Horowitz, Nature, 1979, 22, 655
• [25] P. B. Schift, J. Font, S. B. Horowitz, Proc. Natl. Acad. Sci. U.S.A., 1980, 77, 1561.
• [26] P. Dustin, Microtubules, Springer-Verlag, 1984.
• [27] H. Zhang, P. D. Arpa, L F. Lin, Cancer Cells, 1990, 2, 23.
• [28] Y. Hsiang, L. F. Lin, M. E. Wall, Cancer Res., 1989, 49, 4385.
• [29] S. Kohlmunzer, Farmacja Polska, 1999, 55, 1, 35.
• [30] Computer Aided Molecular Design, Academic Press, NC, San Diego, CA 92101, 1996.
• [31] Ch. Marot, P. H. Chavatte, L. Morion-Allory, J. Med. Chem., 1998, 41, 4453.

Uwagi

PL

Opracowanie rekordu ze środków MEiN, umowa nr SONP/SP/546092/2022 w ramach programu "Społeczna odpowiedzialność nauki" - moduł: Popularyzacja nauki i promocja sportu (2022-2023).